Allergology International最新文献

英文中文

Clinical findings and subjective symptoms in patients with bronchial asthma and chemical hypersensitivity in Japan 日本支气管哮喘和化学过敏症患者的临床表现和主观症状。

IF 6.7 2区医学 Q1 ALLERGY

Allergology International

Pub Date : 2026-01-01 DOI: 10.1016/j.alit.2025.08.008

Sachiko Hojo , Naomi Tsurikisawa , Kentaro Watai , Atsushi Mizukoshi , Yosiyuki Kuroiwa , Kenichi Azuma

Background

Despite advances in pharmacologic therapy, a subset of patients with bronchial asthma (BA) experience persistent symptoms. Multiple chemical sensitivity (MCS), a non-allergic condition triggered by low-level chemical exposures, may be responsible for asthma-like symptoms. Although epidemiological studies have reported a high co-prevalence of MCS and BA, clinical comparisons among patients with BA between those with and without MCS are limited. We aimed to characterize the clinical and symptomatic profiles of patients with BA and comorbid MCS.

Methods

This cross-sectional study included 100 patients with BA treated at Sagamihara Hospital. MCS-related symptoms were evaluated using the Quick Environmental Exposure and Sensitivity Inventory (QEESI). Clinical data including serum total Immunoglobulin E (IgE) levels, eosinophil counts, pulmonary function, hospitalization frequency, comorbidities, and medications were collected by attending physicians. Fifteen patients who exceeded the QEESI MCS cut-off value (BA-MCS group) were compared with 30 age- and sex-matched controls without MCS (BA-control group).

Results

Compared to BA-controls, the BA-MCS group had strong symptoms in multiple organs other than the respiratory system (p = 0.000), exhibited significantly higher percentage forced expiratory volume (%FEV₁) (p = 0.047), lower serum IgE levels (p = 0.028), more frequent hospitalizations (p = 0.002), and higher incidence of atopic dermatitis history (p = 0.001).

Conclusions

The BA-MCS group had a distinct phenotype characterized by preserved lung function, low IgE levels, systemic symptoms, and high disease burden. For these patients, a multidisciplinary approach addressing BA and MCS may be more effective than intensifying asthma pharmacotherapy alone.

背景：尽管药物治疗取得了进展，但一小部分支气管哮喘（BA）患者仍存在持续症状。多重化学敏感性（MCS）是一种由低剂量化学物质暴露引发的非过敏性疾病，可能导致类似哮喘的症状。尽管流行病学研究报道了MCS和BA的高共同患病率，但在患有和不患有MCS的BA患者之间的临床比较有限。我们的目的是描述BA和合并症MCS患者的临床和症状特征。方法：本横断面研究纳入了在相模原医院治疗的100例BA患者。使用快速环境暴露和敏感性量表（QEESI）评估mcs相关症状。临床资料包括血清总免疫球蛋白E （IgE）水平、嗜酸性粒细胞计数、肺功能、住院次数、合并症和药物由主治医生收集。15名超过QEESI MCS临界值的患者（BA-MCS组）与30名年龄和性别匹配的无MCS的对照组（ba -对照组）进行比较。结果：与BA-MCS组相比，BA-MCS组在呼吸系统以外的多器官出现强烈症状（p = 0.000），用力呼气量百分比（%FEV1）显著增加（p = 0.047），血清IgE水平显著降低（p = 0.028），住院次数显著增加（p = 0.002），特应性皮炎病史发生率较高（p = 0.001）。结论：BA-MCS组具有明显的表型，其特征是肺功能保留，IgE水平低，全身性症状，疾病负担高。对于这些患者，多学科治疗BA和MCS可能比单独加强哮喘药物治疗更有效。

{"title":"Clinical findings and subjective symptoms in patients with bronchial asthma and chemical hypersensitivity in Japan","authors":"Sachiko Hojo , Naomi Tsurikisawa , Kentaro Watai , Atsushi Mizukoshi , Yosiyuki Kuroiwa , Kenichi Azuma","doi":"10.1016/j.alit.2025.08.008","DOIUrl":"10.1016/j.alit.2025.08.008","url":null,"abstract":"<div><h3>Background</h3><div>Despite advances in pharmacologic therapy, a subset of patients with bronchial asthma (BA) experience persistent symptoms. Multiple chemical sensitivity (MCS), a non-allergic condition triggered by low-level chemical exposures, may be responsible for asthma-like symptoms. Although epidemiological studies have reported a high co-prevalence of MCS and BA, clinical comparisons among patients with BA between those with and without MCS are limited. We aimed to characterize the clinical and symptomatic profiles of patients with BA and comorbid MCS.</div></div><div><h3>Methods</h3><div>This cross-sectional study included 100 patients with BA treated at Sagamihara Hospital. MCS-related symptoms were evaluated using the Quick Environmental Exposure and Sensitivity Inventory (QEESI). Clinical data including serum total Immunoglobulin E (IgE) levels, eosinophil counts, pulmonary function, hospitalization frequency, comorbidities, and medications were collected by attending physicians. Fifteen patients who exceeded the QEESI MCS cut-off value (BA-MCS group) were compared with 30 age- and sex-matched controls without MCS (BA-control group).</div></div><div><h3>Results</h3><div>Compared to BA-controls, the BA-MCS group had strong symptoms in multiple organs other than the respiratory system (p = 0.000), exhibited significantly higher percentage forced expiratory volume (%FEV<sub>1</sub>) (p = 0.047), lower serum IgE levels (p = 0.028), more frequent hospitalizations (p = 0.002), and higher incidence of atopic dermatitis history (p = 0.001).</div></div><div><h3>Conclusions</h3><div>The BA-MCS group had a distinct phenotype characterized by preserved lung function, low IgE levels, systemic symptoms, and high disease burden. For these patients, a multidisciplinary approach addressing BA and MCS may be more effective than intensifying asthma pharmacotherapy alone.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"75 1","pages":"Pages 134-141"},"PeriodicalIF":6.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study dupilumab联合外用皮质类固醇治疗日本中度至重度特应性皮炎患儿的长期疗效和安全性：一项3期开放标签扩展研究的结果

IF 6.7 2区医学 Q1 ALLERGY

Allergology International

Pub Date : 2026-01-01 DOI: 10.1016/j.alit.2025.09.002

Yoko Kataoka , Motohiro Ebisawa , Akio Tanaka , Mizuho Nagao , Elizabeth Laws , Hisakatsu Nawata , Kazuhiko Arima , Daisuke Watanabe , Xin Lu , Jennifer Maloney , Ariane Dubost-Brama , Ashish Bansal , Kenji Yahata

Background

Dupilumab is approved in Japan for the treatment of atopic dermatitis in patients aged 6 months to 18 years. However, long-term data are lacking in this patient population. Here we report the final analysis of a long-term open-label extension (OLE) of a phase 3 study that assessed dupilumab in Japanese patients aged ≥6 months to <18 years with moderate-to-severe atopic dermatitis inadequately controlled with existing therapies.

Methods

Study participants were randomly assigned to dupilumab or placebo with concomitant topical corticosteroids for 16 weeks, then to open-label dupilumab until approval or for 3 years, whichever came first.

Results

Of the 62 participants randomized, 60 entered the OLE and continued to receive dupilumab (n = 28) or initiated dupilumab (n = 32). Improvements in clinical severity scores seen with dupilumab at Week 16 persisted up to Week 116, as confirmed by several efficacy endpoints (proportion of patients who achieved ≥75 % or ≥90 % improvement in Eczema Area and Severity Index [EASI] score, and Investigator's Global Assessment score of 0/1, and percent change in EASI scores from baseline). During the dupilumab exposure period, 93.5 % of patients experienced a treatment-emergent adverse event (TEAE). No adverse events leading to death, or TEAEs leading to study treatment discontinuation were observed during the OLE period. One (3.1 %) treatment-emergent positive anti-drug antibody response was observed during the OLE period in the placebo/dupilumab group.

Conclusions

This analysis supports the long-term efficacy and safety of dupilumab in Japanese patients aged ≥6 months to <18 years with moderate-to-severe atopic dermatitis.

背景：Dupilumab在日本被批准用于治疗6个月至18岁的特应性皮炎患者。然而，缺乏这一患者群体的长期数据。在此，我们报告了一项长期开放标签扩展（OLE）的3期研究的最终分析，该研究评估了dupilumab在年龄≥6个月的日本患者中的应用。方法：研究参与者被随机分配到dupilumab或安慰剂并伴有局部皮质类固醇治疗16周，然后使用开放标签dupilumab直到批准或3年，以先到者为例。结果：在随机分配的62名参与者中，60名进入OLE并继续接受dupilumab （n = 28）或开始使用dupilumab （n = 32）。dupilumab在第16周临床严重程度评分的改善持续到第116周，几个疗效终点（湿疹面积和严重程度指数[EASI]评分改善≥75%或≥90%的患者比例，研究者的全球评估评分为0/1，EASI评分从基线变化的百分比）证实了这一点。在dupilumab暴露期间，93.5%的患者经历了治疗出现的不良事件（TEAE）。在OLE期间未观察到导致死亡的不良事件或导致研究治疗中断的teae。安慰剂/杜匹单抗组在OLE期间观察到1例（3.1%）治疗出现的阳性抗药抗体反应。结论：该分析支持dupilumab在年龄≥6个月至6岁的日本患者中的长期有效性和安全性

{"title":"Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study","authors":"Yoko Kataoka , Motohiro Ebisawa , Akio Tanaka , Mizuho Nagao , Elizabeth Laws , Hisakatsu Nawata , Kazuhiko Arima , Daisuke Watanabe , Xin Lu , Jennifer Maloney , Ariane Dubost-Brama , Ashish Bansal , Kenji Yahata","doi":"10.1016/j.alit.2025.09.002","DOIUrl":"10.1016/j.alit.2025.09.002","url":null,"abstract":"<div><h3>Background</h3><div>Dupilumab is approved in Japan for the treatment of atopic dermatitis in patients aged 6 months to 18 years. However, long-term data are lacking in this patient population. Here we report the final analysis of a long-term open-label extension (OLE) of a phase 3 study that assessed dupilumab in Japanese patients aged ≥6 months to <18 years with moderate-to-severe atopic dermatitis inadequately controlled with existing therapies.</div></div><div><h3>Methods</h3><div>Study participants were randomly assigned to dupilumab or placebo with concomitant topical corticosteroids for 16 weeks, then to open-label dupilumab until approval or for 3 years, whichever came first.</div></div><div><h3>Results</h3><div>Of the 62 participants randomized, 60 entered the OLE and continued to receive dupilumab (n = 28) or initiated dupilumab (n = 32). Improvements in clinical severity scores seen with dupilumab at Week 16 persisted up to Week 116, as confirmed by several efficacy endpoints (proportion of patients who achieved ≥75 % or ≥90 % improvement in Eczema Area and Severity Index [EASI] score, and Investigator's Global Assessment score of 0/1, and percent change in EASI scores from baseline). During the dupilumab exposure period, 93.5 % of patients experienced a treatment-emergent adverse event (TEAE). No adverse events leading to death, or TEAEs leading to study treatment discontinuation were observed during the OLE period. One (3.1 %) treatment-emergent positive anti-drug antibody response was observed during the OLE period in the placebo/dupilumab group.</div></div><div><h3>Conclusions</h3><div>This analysis supports the long-term efficacy and safety of dupilumab in Japanese patients aged ≥6 months to <18 years with moderate-to-severe atopic dermatitis.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"75 1","pages":"Pages 142-149"},"PeriodicalIF":6.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145309670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 6.7 2区医学 Q1 ALLERGY

Allergology International

Pub Date : 2026-01-01

引用次数: 0

IF 6.7 2区医学 Q1 ALLERGY

Allergology International

Pub Date : 2026-01-01

引用次数: 0

Sputum symptoms and microbiome in type 2 airway diseases with mucus plugs on computed tomography 2型气道疾病的痰症状和微生物组与粘液塞的计算机断层扫描

IF 6.7 2区医学 Q1 ALLERGY

Allergology International

Pub Date : 2026-01-01 DOI: 10.1016/j.alit.2025.10.002

Naoya Tanabe , Hisako Matsumoto , Chie Morimoto , Yusuke Hayashi , Hironobu Sunadome , Atsuyasu Sato , Susumu Sato , Toyohiro Hirai

引用次数: 0

IF 6.7 2区医学 Q1 ALLERGY

Allergology International

Pub Date : 2026-01-01

引用次数: 0

IF 6.7 2区医学 Q1 ALLERGY

Allergology International

Pub Date : 2026-01-01

引用次数: 0

IF 6.7 2区医学 Q1 ALLERGY

Allergology International

Pub Date : 2026-01-01

引用次数: 0

Clinical utility of YKL-40 for understanding pathophysiology of obstructive airway disorders YKL-40在了解阻塞性气道疾病病理生理方面的临床应用。

IF 6.7 2区医学 Q1 ALLERGY

Allergology International

Pub Date : 2026-01-01 DOI: 10.1016/j.alit.2025.05.004

Yasuhito Suzuki, Junpei Saito , Masami Kikuchi, Suguru Sato, Atsuro Fukuhara, Mami Rikimaru, Hikaru Tomita, Kentaro Kazama, Koshi Saito, Rina Harigane, Riko Sato, Ryuki Yamada, Natsumi Watanabe, Takashi Umeda, Ryuichi Togawa, Yuki Sato, Hiroyuki Minemura, Takefumi Nikaido, Kenya Kanazawa, Xintao Wang, Yoko Shibata

Background

Chitinase-3-like protein 1 (YKL-40) has been reported as a biomarker of neutrophilic airway inflammation in obstructive airway disorders. However, the pathophysiological features of YKL-40 remain unclear. The aim of the study is to evaluate the associations between YKL-40 and clinical features in patients with asthma, chronic obstructive pulmonary disease (COPD), or asthma-COPD overlap (ACO).

Methods

Serum and sputum YKL-40 levels were measured in 46 asthmatics, 35 COPD, and 32 ACO patients.

Results

Serum YKL-40 levels were elevated in the COPD and ACO patients, and sputum YKL-40 levels were higher in the COPD patients compared to the asthmatics. Both serum and sputum YKL-40 levels positively correlated with sputum neutrophils. Only serum YKL-40 levels negatively correlated with FEV₁ (%predicted), FEV₁/FVC, and annual decline in FEV₁. In 15 patients whose paired serum samples were obtained within 6 months, changes in serum YKL-40 levels showed a significant positive correlation with those in FEV₁. Furthermore, patients who had experienced exacerbations either in the past year or the following year showed significantly greater serum, but not sputum, YKL-40 levels. Sputum YKL-40 levels showed significant correlations with scores on the COPD assessment test and modified Medical Research Council dyspnea scale.

Conclusions

Serum and sputum YKL-40 may reflect distinct clinical features in obstructive airway disorders. Serum YKL-40 may provide beneficial information on predicting obstructive neutrophilic inflammation and exacerbations, whilst sputum YKL-40 may offer valuable insights for evaluating ongoing symptoms. Concomitant measurement of YKL-40 in serum and sputum might be more useful than individual measurement.

背景：几丁质酶-3样蛋白1 （YKL-40）已被报道为阻塞性气道疾病中性粒细胞气道炎症的生物标志物。然而，YKL-40的病理生理特征尚不清楚。该研究的目的是评估哮喘、慢性阻塞性肺疾病（COPD）或哮喘-COPD重叠（ACO）患者的YKL-40与临床特征之间的关系。方法：对46例哮喘、35例COPD、32例ACO患者进行血清及痰中YKL-40水平测定。结果：COPD和ACO患者血清YKL-40水平均升高，且COPD患者痰中YKL-40水平高于哮喘患者。血清和痰中YKL-40水平与痰中中性粒细胞呈正相关。只有血清YKL-40水平与FEV1（预测百分比）、FEV1/FVC和FEV1年下降呈负相关。在6个月内获得配对血清样本的15例患者中，血清YKL-40水平的变化与FEV1的变化呈显著正相关。此外，在过去一年或接下来一年经历加重的患者血清中YKL-40水平明显升高，但痰中没有。痰液中YKL-40水平与COPD评估测试和改良的医学研究委员会呼吸困难量表得分有显著相关性。结论：血清和痰液中YKL-40可反映阻塞性气道疾病的不同临床特征。血清YKL-40可能为预测阻塞性中性粒细胞炎症和恶化提供有益信息，而痰液YKL-40可能为评估持续症状提供有价值的见解。同时测定血清和痰中YKL-40可能比单独测定更有用。

{"title":"Clinical utility of YKL-40 for understanding pathophysiology of obstructive airway disorders","authors":"Yasuhito Suzuki, Junpei Saito , Masami Kikuchi, Suguru Sato, Atsuro Fukuhara, Mami Rikimaru, Hikaru Tomita, Kentaro Kazama, Koshi Saito, Rina Harigane, Riko Sato, Ryuki Yamada, Natsumi Watanabe, Takashi Umeda, Ryuichi Togawa, Yuki Sato, Hiroyuki Minemura, Takefumi Nikaido, Kenya Kanazawa, Xintao Wang, Yoko Shibata","doi":"10.1016/j.alit.2025.05.004","DOIUrl":"10.1016/j.alit.2025.05.004","url":null,"abstract":"<div><h3>Background</h3><div>Chitinase-3-like protein 1 (YKL-40) has been reported as a biomarker of neutrophilic airway inflammation in obstructive airway disorders. However, the pathophysiological features of YKL-40 remain unclear. The aim of the study is to evaluate the associations between YKL-40 and clinical features in patients with asthma, chronic obstructive pulmonary disease (COPD), or asthma-COPD overlap (ACO).</div></div><div><h3>Methods</h3><div>Serum and sputum YKL-40 levels were measured in 46 asthmatics, 35 COPD, and 32 ACO patients.</div></div><div><h3>Results</h3><div>Serum YKL-40 levels were elevated in the COPD and ACO patients, and sputum YKL-40 levels were higher in the COPD patients compared to the asthmatics. Both serum and sputum YKL-40 levels positively correlated with sputum neutrophils. Only serum YKL-40 levels negatively correlated with FEV<sub>1</sub> (%predicted), FEV<sub>1</sub>/FVC, and annual decline in FEV<sub>1</sub>. In 15 patients whose paired serum samples were obtained within 6 months, changes in serum YKL-40 levels showed a significant positive correlation with those in FEV<sub>1</sub>. Furthermore, patients who had experienced exacerbations either in the past year or the following year showed significantly greater serum, but not sputum, YKL-40 levels. Sputum YKL-40 levels showed significant correlations with scores on the COPD assessment test and modified Medical Research Council dyspnea scale.</div></div><div><h3>Conclusions</h3><div>Serum and sputum YKL-40 may reflect distinct clinical features in obstructive airway disorders. Serum YKL-40 may provide beneficial information on predicting obstructive neutrophilic inflammation and exacerbations, whilst sputum YKL-40 may offer valuable insights for evaluating ongoing symptoms. Concomitant measurement of YKL-40 in serum and sputum might be more useful than individual measurement.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"75 1","pages":"Pages 52-61"},"PeriodicalIF":6.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of allergen signatures with individualized allergic phenotypes 过敏原特征与个体化过敏表型的关联。

IF 6.7 2区医学 Q1 ALLERGY

Allergology International

Pub Date : 2026-01-01 DOI: 10.1016/j.alit.2025.09.003

Dachan Kim , Hyung-Ju Cho , Chang-Hoon Kim , Min-Seok Rha

Background

Allergen sensitization patterns are heterogeneous, and their clinical relevance is often obscured by extensive cross-reactivity. We applied non-negative matrix factorization (NMF) to disentangle overlapping immunoglobulin E (IgE) signals and define clinically meaningful allergen signatures in a large Korean cohort.

Methods

We analyzed 45,065 patients who underwent multiplex allergen testing (35 inhalants and food components) between 2010 and 2025. Class-scaled specific IgE values (0–6) were factorized by NMF (k = 4). Signature weights were related to asthma, allergic rhinitis, and atopic dermatitis using multivariable logistic regression and to peripheral eosinophil counts and total IgE using age- and sex-adjusted linear models.

Results

Four signatures—mite, grass/weed, pet, and tree—explained 77.7 % of the variance in sensitization. The mite signature predominated (57.6 % of patients) and was strongly associated with allergic rhinitis (adjusted OR: 7.21, 95 % CI: 5.66–9.16), as well as marked increases in eosinophils and total IgE. The pet signature was the strongest predictor of asthma (OR: 8.90, 6.48–12.24). The tree signature showed the strongest association with atopic dermatitis (OR: 6.27, 3.81–10.32) and broader multisystem allergic morbidity. The grass/weed signature exhibited a biphasic age trajectory with a late-adult resurgence but had modest clinical impact. All signatures were significant and graded as determinants of blood eosinophil counts and IgE levels.

Conclusions

Data-driven factorization of multiplex IgE panels yields portable allergen signatures that refine attribution of asthma, allergic rhinitis, and atopic dermatitis and link serologic patterns to systemic inflammation.

背景：过敏原致敏模式是异质的，它们的临床相关性常常被广泛的交叉反应性所掩盖。我们应用非负矩阵分解（NMF）来解开重叠的免疫球蛋白E （IgE）信号，并在一个大型韩国队列中定义有临床意义的过敏原特征。方法：我们分析了2010年至2025年间接受多重过敏原检测（35种吸入剂和食物成分）的45,065例患者。分类特异性IgE值（0-6）由NMF因子分解（k = 4）。特征权重与哮喘、变应性鼻炎和特应性皮炎相关，与外周嗜酸性粒细胞计数和总IgE相关，采用年龄和性别调整线性模型。结果：螨、草/杂草、宠物和树这四个特征解释了77.7%的致敏差异。螨特征占主导地位（57.6%的患者），与变应性鼻炎密切相关（调整后的OR: 7.21, 95% CI: 5.66-9.16），嗜酸性粒细胞和总IgE显著增加。宠物特征是哮喘的最强预测因子（OR: 8.90, 6.48-12.24）。树特征显示与特应性皮炎（OR: 6.27, 3.81-10.32）和更广泛的多系统过敏性发病率的最强关联。草/杂草特征表现出双相年龄轨迹，成年后期复苏，但临床影响不大。所有的特征都是显著的，并被分级为血液嗜酸性粒细胞计数和IgE水平的决定因素。结论：多重IgE面板的数据驱动因子分解产生便携式过敏原特征，可细化哮喘，过敏性鼻炎和特应性皮炎的归因，并将血清学模式与全身性炎症联系起来。

{"title":"Association of allergen signatures with individualized allergic phenotypes","authors":"Dachan Kim , Hyung-Ju Cho , Chang-Hoon Kim , Min-Seok Rha","doi":"10.1016/j.alit.2025.09.003","DOIUrl":"10.1016/j.alit.2025.09.003","url":null,"abstract":"<div><h3>Background</h3><div>Allergen sensitization patterns are heterogeneous, and their clinical relevance is often obscured by extensive cross-reactivity. We applied non-negative matrix factorization (NMF) to disentangle overlapping immunoglobulin E (IgE) signals and define clinically meaningful allergen signatures in a large Korean cohort.</div></div><div><h3>Methods</h3><div>We analyzed 45,065 patients who underwent multiplex allergen testing (35 inhalants and food components) between 2010 and 2025. Class-scaled specific IgE values (0–6) were factorized by NMF (k = 4). Signature weights were related to asthma, allergic rhinitis, and atopic dermatitis using multivariable logistic regression and to peripheral eosinophil counts and total IgE using age- and sex-adjusted linear models.</div></div><div><h3>Results</h3><div>Four signatures—mite, grass/weed, pet, and tree—explained 77.7 % of the variance in sensitization. The mite signature predominated (57.6 % of patients) and was strongly associated with allergic rhinitis (adjusted OR: 7.21, 95 % CI: 5.66–9.16), as well as marked increases in eosinophils and total IgE. The pet signature was the strongest predictor of asthma (OR: 8.90, 6.48–12.24). The tree signature showed the strongest association with atopic dermatitis (OR: 6.27, 3.81–10.32) and broader multisystem allergic morbidity. The grass/weed signature exhibited a biphasic age trajectory with a late-adult resurgence but had modest clinical impact. All signatures were significant and graded as determinants of blood eosinophil counts and IgE levels.</div></div><div><h3>Conclusions</h3><div>Data-driven factorization of multiplex IgE panels yields portable allergen signatures that refine attribution of asthma, allergic rhinitis, and atopic dermatitis and link serologic patterns to systemic inflammation.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"75 1","pages":"Pages 150-157"},"PeriodicalIF":6.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145309720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Allergology International

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀